Drug Profile
Tobramycin inhalation - PlumeStars
Latest Information Update: 23 Dec 2021
Price :
$50
*
At a glance
- Originator PlumeStars
- Class Aminoglycosides; Anti-infectives; Antibacterials; Antibronchitics; Small molecules
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 26 Aug 2016 Chemical structure information added
- 10 Aug 2016 Investigation in Cystic fibrosis-associated respiratory tract infections in Italy (Inhalation)